While Immunic beat EPS estimates, the lack of revenue growth may temper investor enthusiasm. Historical data shows a previous earnings miss led to a share price decline, suggesting that the market is sensitive to Immunic's earnings performance. However, the beat on EPS could provide some positive sentiment, potentially balancing out the impact on the stock price in the short term.